CD19 CAR-T Cell Therapy With Lymphodepletion for Refractory B-Cell Cancers
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing cancer treatments, including chemotherapy, radiotherapy, and immunotherapy, are often ineffective for relapsed or refractory mantle cell lymphoma (MCL) and B cell acute lymphoblastic leukemia (B cell ALL), necessitating the development of more effective therapeutic strategies.
Innovation Solution
Administration of autologous T cells genetically modified to express a chimeric antigen receptor (CAR) targeting CD19, combined with optimized lymphodepleting chemotherapy and bridging therapies, to enhance the efficacy of CAR-T cell therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (chemotherapy, radiotherapy, immunotherapy) are used for relapsed or refractory MCL and B cell ALL, then treatment options are available, but treatment effectiveness is insufficient
Solution Approach 1:
The patent uses CAR-T cells as an intermediary agent that specifically targets CD19 antigen on cancer cells. The CAR-T cells are engineered to recognize and bind to CD19, bringing the cytotoxic effect directly to the cancer cells while sparing normal cells, thus improving treatment effectiveness and reducing harmful effects on healthy tissues
Solution Approach 2:
The patent replaces conventional chemical chemotherapy agents with a biological mechanism where genetically modified T cells directly recognize and destroy cancer cells through antigen-specific binding and cytotoxic granule release, substituting chemical warfare with a more precise biological recognition and destruction system
2Reliability
If CAR-T cell therapy is administered to improve treatment outcomes, then cancer cell targeting capability increases, but cytokine release syndrome and neurologic toxicity occur
Solution Approach 1:
The patent applies preliminary lymphodepleting chemotherapy before CAR-T cell infusion to clear out immunosuppressive cells and create a more favorable immune environment. This preliminary action reduces the risk of cytokine release syndrome by pre-conditioning the patient's immune system to better tolerate the incoming CAR-T cells
Solution Approach 2:
The patent implements monitoring of cytokine levels and clinical symptoms to detect early signs of cytokine release syndrome and neurologic toxicity. Based on this feedback, the treatment protocol can be adjusted by administering cytokine inhibitors or adjusting CAR-T cell dosing to mitigate harmful effects while maintaining cancer cell targeting effectiveness
3Productivity
If lymphodepleting chemotherapy is optimized to enhance CAR-T cell efficacy, then CAR-T cell expansion and persistence improve, but treatment complexity and patient burden increase
Solution Approach 1:
The patent optimizes the parameters of lymphodepleting chemotherapy by adjusting drug dosages, administration timing, and combination regimens to achieve the ideal balance between CAR-T cell expansion and patient tolerance. By fine-tuning these parameters, the protocol maximizes CAR-T cell efficacy while keeping treatment complexity manageable through evidence-based standardization
Data Source
AI summary
Provided herein are methods for preparing, producing, processing, culturing, isolating, or making cells suitable for immune or cell therapy, and for their use in cell therapy.